Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG /Th2 T Stem Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis

NCT06169176 is registered in ClinicalTrials.gov with Rapa Therapeutics LLC as lead sponsor.

NCT NCT06169176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06169176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG /Th2 T Stem Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis
Lead sponsor
Rapa Therapeutics LLC
Phase
Expanded access
Overall status
Temporarily not available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis